PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE JAN 18 2002 PATENT & TRADEMARK OFFICE

RECEIVED JAN 23 2002 TECHNOLOGY CENTER 1600/2900

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: December 28, 2001

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	09/851,422
Filing Date	05/09/2001
First Named Inventor	Xianxhang YU
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	035879-0122

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KAC MS	A1	6,255,282	B1	Jaynes	07/03/2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
KAC MS	A2	PCT	WO 97/33908		Rivett et al.	09/18/1997		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
KAC MS	A3	BLONDELLE et al., "Hemolytic and Antimicrobial Activities of the Twenty-Four Individual Omission Analogues of Melittin," *Biochemistry*, 1991, pp. 4671-4678, Vol. 30, American Chemical Society.	
	A4	DEMPSEY et al., "Contributioon of Proline-14 to the Structure and Actions of Melittin," *FEBS Letters*, 1991, pp. 240-244, Vol. 281, No. 1,2, Elsevier Science Publishers B.V.	
	A5	LEIPPE et al., "Cytolytic and Antibacterial Activity of Synthetic Peptides Derived from amoebapore, the Pore-Forming Peptide of *Entamoeba Histolytica*," *Proc. Natl. Acad. Sci. USA*, 1994, pp. 2602-2606, Vol. 91.	
	A6	ANDRÄ et al., "Shortened Amoebapore Analogs with Enhanced Antibacterial and Cytolytic Activity," *FEBS Letters*, 1996, pp. 96-100, Vol. 385, Federation of European Biochemical Societies.	
	A7	SHAI et al., "Diastereomers of Cytolysins, a Novel Class of Potent Antibacterial Peptides," *Journal Biological Chemistry*, 1996, pp. 7305-7308, Vol. 271 No. 13, The American Society for Biochemistry and Molecular Biology, Inc.	

Examiner Signature	Karen A. Gamble	Date Considered	1/8/03 5-6-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE JAN 18 2002 PATENT & TRADEMARK OFFICE

RECEIVED JAN 23 2002 TECH CENTER 1600/2900

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: December 28, 2001

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	09/851,422
Filing Dat	05/09/2001
First Named Inventor	Xianxhang YU
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	035879-0122

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
KAC MJ	A8	WERKMEISTER et al., "The Effect of Sequence Variations and Structure on the Cytolytic Activity of Melittin Peptides," *Biochimica et Biophysica Acta*, 1993, pp. 50-54, Vol. 1157, Elsevier Science Publishers B.V.	
	A9	LEIPPE et al., "Pore-Forming Peptide of Pathogenic *Entamoeba Histolytica*," *Proc. Natl. Acad. Sci. USA*, 1991, pp. 7659-7663, Vol. 88.	
	A10	HOROSZEWICZ et al., "LNCaP Model of Human Prostatic Carcinoma[1]," *Cancer Research*, 1983, pp. 1809-1818, Vol. 43, No. 4, Dept. of Biological Resources, Roswell Park Memorial Inst. Buffalo, New York.	
	A11	PINTO et al., "Prostate Specific Membrane Antigen, a Unique Glutamate Carboxypeptidase: A Review of Recent Findings," *The Prostate Journal*, 1999, pp. 15-26, Vol. 1, No. 1, Blackwell Science, Inc.	
	A12	LOPES et al., "Immunohistochemical and Pharmacokinetic Characterization of the Site-Specific Immunoconjugate CYT-356 Derived from Antiprostate Monoclonal Antibody," *Cancer Research*, 1990, pp. 6423-6429, Vol. 50, American Association for Cancer Research.	
	A13	TROYER et al., "Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids," *Int. J. Cancer*, 1995, pp. 552-558, Vol. 62, Wiley-Liss, Inc.	
	A14	WALLRAPP et al., "A Novel Transmembrane Serine Protease (TMPRSS3) Overexpressed in Pancreatice Cancer[1,2]," *Cancer Research*, 2000, pp. 2602-2606, Vol. 60, No. 10, American Association for Cancer Research.	
	A15	WRIGHT et al., "Expression of Prostate-Specific membrane Antigen in Normal, Benign, and Malignant Prostate Tissues," *Urol. Oncol.*, 1995, pp. 18-28, Vol. 1, Elsevier Science Inc., New York.	
	A16	PRAUSNITZ et al., "Electroporation of Mammalian Skin: A Mechanism to Enhance Transdermal Drug Delivery", Proc. Natl. Acad. Sci. USA, 1993, pp. 10504-10508, Vol. 90, No. 22, Medical Sciences, NIH	
	A17	WALLACE et al., "Stand and Deliver: Getting Peptide Drugs into the Body", Science, 1993, pp. 912-913, Vol. 260, American Association for the Advancement of Science	
	A18	ANDREU et al., "Solid-Phase Synthesis of Cecropin A and Related Peptides", Proc. Natl. Acad. Sci. USA, 1983, pp. 6475-6479, Vol. 80, No. 21, Biochemistry, Biological Science	
	A19	ANDREU et al., "N-Terminal Analogues of Cecropin A: Synthesis, Antibacterial Activity, and Confromational Properties", Biochemistry, 1985, pp. 1683-1688, Vol. 24, No. 7, American Chemical Society	
	A20	FINK et al., "Design, Synthesis and Antibacterial Activity of Cecropin-Like Model Peptides", Int. J. Peptide Protein Res., 1989, pp. 412-421, Vol. 33, No. 6, The Rockefeller University, New York, New York	
	A21	FINK et al., "The Chemical Synthesis of Cecropin D and an Analog with Enhanced Antibacterial Activity", J. of Biological Chemistry, 1989, pp. 6260-6267, Vol. 264, No. 11, American Society for Biochemistry and Molecular Biology, Inc. Rockefeller University, New York	

Karen G. Gamble 1/4/05

Examiner Signatur		Date Considered	5-6-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: December 28, 2001

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	09/851,422
Filing Date	05/09/2001
First Named Inventor	Xianxhang YU
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	035879-0122

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
MY	A22	ARGIOLAS et al., "Bombolitins, a New Class of Mast Cell Degranulating Peptides from the Venom of the Bumblebee Megabombus Pennsylvanicus", J. of Biological Chemistry, 1985, pp. 1437-1444, Vol. 260, No. 3, American Society of Biological Chemists, Inc.	
	A23	YOUNG et al., "Characterization of a Member Pore-Forming Protein From Entamoeba Histolytica", J. Exp. Med. 1982, pp. 1677-1690, Vol. 156, No. 6, The Rockefeller University Press	
	A24	LYNCH et al., "An Ion-Channel Forming Protein Produced by Entamoeba Histolytica", The EMBO Journal, 1982, pp. 801-804, Vol. 1, No. 7, IRL Press Limited, Oxford, England	
	A25	YOUNG et al., "Molecular Mechanisms of Cytotoxicity Mediated by Entamoeba Histolytica: Characterization of a Pore-Forming Protein (PFP)", J. of Cellular Biochemistry, 1985, pp. 299-308, Vol. 29 No. 4, Alan R. Liss, Inc.	
	A26	ROSENBERG et al., "Isolation, Characterization and Partial Purification of a Transferable Membrane Channel (Amoebapore) Produced by Entamoeba Histolytica", Molecular and Biochemical Parasitology, 1989, pp. 237-248, Vol. 33, No. 3, Elsevier Science Publishers B.V.	
	A27	JANSSON et al., "Coding of Hemolysins Within the Ribosomal RNA Repeat on a Plasmid in Entamoeba Histolytica", Science, 1994, pp. 11440-1443, Vol. 263, American Association for the Advancement of Science	
	A28	WOODLE e tal., "Prolonged Systemic Delivery of Peptide Drugs by Long-Circulating Liposomes: Illustration with Vasopressin in the Brattleboro Rat", Pharmaceutical Research, 1992, Vol. 9, No. 2, Plenum Press, New York	

Examiner Signature		Date Considered	5-6-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		035879-0122	09/851,422
INFORMATION DISCLOSURE CITATION		APPLICANT	
		Xianxhang YU, et al.	
		FILING DATE	GROUP ART UNIT
(Use several sheets if necessary)		05/09/2001	1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

KAC	A1 ✓	CH. NAGARJUN RAO et al., "Role of amino groups in the biological activity of cytotoxin-3 from indian cobra venon," *Recent Adv. Toxinol. Res.*, (1992), 1:514-520 (XP001031413); summary page 514, last paragraph – page 515, paragraph 1, page 517, paragraph 3 – page 518, paragraph 1; tables 1, 2.
	A2 ✓	S. BOURDENET et al., "The cytotoxicity of Pseudomonas exotoxin A, inactivated by modification of the cell-binding domain I, is restored when conjugated to an erythroid cell-specific targeting agent," *Cancer Letters*, (1990), 50(2):121-127 (XP001031414); summary page 124, left-hand column, paragraph 2 – page 126, right-hand column, last paragraph.
	A3 ✓	SHINNE-REN LIN et al., "Chemical modification of amino groups in cardiotoxin III from Taiwan cobra (Naja naja atra) venom," *Biochemistry and Molecular Biology International*, (1993) 31(1):175-184 (XP001031369) page 178, paragraph 1 – page 183, paragraph 1 summary.
	A4	E. SCHROEDER et al., "Hemolytic activity and action on the surface tension of aequeous solutions of synthetic melittins," *Experientia* (1971) 27(7):764-765 (XP001031342).
	A5	JÖRG ANDRÄ et al., "Shortened amoebapore analogs with enhanced antibacterial and cytolytic activity," *FEBS Letters* (1996) 385:96-100 (XP002182888) abstract, page 97, right-hand column, paragraph 2 – page 100, right hand column, paragraph 1.

EXAMINER	DATE CONSIDERED
Karen J. Gaulte	1/4/05
Mitchell P	5-6-03

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line thr ugh citation if not in c nformance and not considered. Includ any copy of this f rm with n xt c mmunication to applicant.**